Leonardo Spatola

Dr. Leonardo Spatola

Renal and Dialysis Unit, Ospedale Sant'Antonio Abate, Trapani, Italy
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Metabolism
Verified
Journal Article
Closed access
Leonardo SpatolaLeonardo Spatola
Leonardo Spatola
PFPietro Manuel Ferraro
Pietro Manuel Ferraro
GGGiovanni Gambaro
Giovanni Gambaro
SBSalvatore Badalamenti
Salvatore Badalamenti
MDMarco Dauriz
Marco Dauriz

16 April 2016 in Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
Leonardo SpatolaLeonardo Spatola
Leonardo Spatola
SASimeone Andrulli
Simeone Andrulli

19 May 2022 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
SASimeone Andrulli
Simeone Andrulli
MRMichele Rossini
Michele Rossini
GGGiuseppe Gigliotti
Giuseppe Gigliotti
GMGaetano La Manna
Gaetano La Manna
SFSandro Feriozzi
Sandro Feriozzi
ITITA-KID-BIO-Group
ITA-KID-BIO-Group
Background: The known risks and benefits of native kidney biopsies are mainly based on the findings of retrospective studies. The aim of this multicentre prospective study was to evaluate the safety of percutaneous renal biopsies and quantify biopsy-related complication rates in Italy.Methods: The study examined the results of native kidney biopsies performed in 54 Italian nephrology centres between 2012 and 2020. The primary outcome was the rate of major complications 1 day after the procedure, or for longer if it was necessary to evaluate the evolution of a complication. Centre and patient risk predictors were analysed using multivariate logistic regression.Results: Analysis of 5304 biopsies of patients with a median age of 53.2 years revealed 400 major complication events in 273 patients (5.1%): the most frequent was a ≥2 g/dL decrease in haemoglobin levels (2.2%), followed by macrohaematuria (1.2%), blood transfusion (1.1%), gross haematoma (0.9%), artero-venous fistula (0.7%), invasive intervention (0.5%), pain (0.5%), symptomatic hypotension (0.3%), a rapid increase in serum creatinine levels (0.1%) and death (0.02%). The risk factors for major complications were higher plasma creatinine levels [odds ratio (OR) 1.12 for each mg/dL increase, 95% confidence interval (95% CI) 1.08–1.17], liver disease (OR 2.27, 95% CI 1.21–4.25) and a higher number of needle passes (OR for each pass 1.22, 95% CI 1.07–1.39), whereas higher proteinuria levels (OR for each g/day increase 0.95, 95% CI 0.92–0.99) were protective.Conclusions: This is the first multicentre prospective study showing that percutaneous native kidney biopsies are associated with a 5% risk of a major post-biopsy complication. Predictors of increased risk include higher plasma creatinine levels, liver disease and a higher number of needle passes.

28 June 2018 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
Leonardo SpatolaLeonardo Spatola
Leonardo Spatola
EGElena Generali
Elena Generali
CAClaudio Angelini
Claudio Angelini
SBSalvatore Badalamenti
Salvatore Badalamenti
CSCarlo Selmi
Carlo Selmi

5 December 2016 in Urolithiasis
Verified
Journal Article
Closed access
PDF file
Leonardo SpatolaLeonardo Spatola
Leonardo Spatola
CAClaudio Angelini
Claudio Angelini
SBSalvatore Badalamenti
Salvatore Badalamenti
SMSilvio Maringhini
Silvio Maringhini
GGGiovanni Gambaro
Giovanni Gambaro

24 November 2017 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
Leonardo SpatolaLeonardo Spatola
Leonardo Spatola
SFSilvia Finazzi
Silvia Finazzi
CAClaudio Angelini
Claudio Angelini
MDMarco Dauriz
Marco Dauriz
SBSalvatore Badalamenti
Salvatore Badalamenti
Diabetes is a complex disease of increasingly common occurrence worldwide. Attaining optimal glycemic control is the main challenge to prevent the development of diabetes-related complications and/or to stop their progression. In recent years, the pharmacologic toolkit for the treatment of diabetes has considerably expanded, thus paving the way to more pathophysiology-oriented therapies. For instance, the sodium-glucose cotransporters SGLT2 and SGLT1 have been in the spotlight because of better knowledge of their physiology and therapeutic potential. At present, whereas the SGLT2 inhibitors are widely applied in current clinical practice as an effective and well-tolerated treatment that increases the urinary excretion of glucose, less is known about the use of SGLT1 inhibitors. SGLT1s are of primary importance in the small intestine, an organ that does not express SGLT2, while in the kidney they are expressed in the late renal proximal tubules, where it reabsorbs the glucose escaped from the upstream SGLT2. Hence, SGLT1-mediated glucose reabsorption in the kidney is increased when the tubular glucose load overwhelms the capacity of SGLT2 or when the latter is inhibited. The role of SGLT1 in intestinal and renal glucose transport makes the transporter a potential target for antidiabetic therapy. Here, we briefly report the evidence on LX2761, a new inhibitor against SGLT1 and SGLT2 in vitro, which acts in vivo as a selective inhibitor of SGLT1 in the gastrointestinal tract. LX2761 improves glycemic control without the glycosuria-related side effects of SGLT2 inhibitors, particularly genitourinary tract infections. However, whether it represents a valid therapeutic option for all patients with diabetes or is more appropriate for specific phenotypes, e.g., patients with concomitant diabetes and chronic kidney disease, who may benefit less from the renal mechanism of selective SGLT2 inhibitors, remains to be tested in large randomized controlled trials.